natgillin/translations-raw huggingface dataset:
Weight loss at two years was 5.1 kg for patients who received ACOMPLIA 20 mg and 1.2 kg for placebo (Difference -3.8 kg; CI95% -4.4, -3.3; p< 0.001). 
Zmanjšanje telesne mase po dveh letih je bilo pri bolnikih, ki so dobivali zdravilo ACOMPLIA 20 mg, 5,1 kg in pri bolnikih, ki so dobivali placebo, 1,2 kg (razlika -3,8 kg, IZ95 % -4,4, -3,3; p<0,001).
Diarrhoea Vomiting 
Žilne bolezni valovi vročine
The steady-state pharmacokinetics of an ethinyl estradiol/levonorgestrel combination oral contraceptive were not significantly altered by concomitant administration of rimonabant. 
Sočasna uporaba rimonabanta ni pomembno spremenila farmakokinetike kombiniranega peroralnega kontraceptiva z etinilestradiolom/levonorgestrelom v stanju dinamičnega ravnovesja.
The active substance is rimonabant. 
Zdravilna učinkovina je rimonabant.
MARKETING AUTHORIZATION NUMBER 
IMETNIK DOVOLJENJA ZA PROMET
There are limited data in patients with moderate renal impairment and no data in patients with severe renal impairment. 
O bolnikih z zmerno okvaro ledvic so na voljo le omejeni podatki.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton for the presentations of 14, 28, 30 56, 70, 84, 90 and 98 film-coated tablets in blisters 
PODATKI NA ZUNANJI OVOJNINI Škatla s 14, 28, 30, 56, 70, 84, 90 in 98 filmsko obloženimi tabletami v pretisnih omotih
Skin and subcutaneous tissue disorders 
Bolezni kože in podkožja srbenje hiperhidroza nočno znojenje
In single- and repeat-dose studies, the Cmax and AUC of rimonabant were similar in healthy Japanese and Caucasian subjects, whereas elimination half-life was shorter in Japanese subjects (3-4 days) compared to Caucasian subjects (about 9 days). 
Eliminacijski razpolovni čas pa je bil pri japonskih preiskovancih krajši (od 3 do 4 dni) kot pri belcih (okrog 9 dni).
ACOMPLIA 20 mg film-coated tablets 
ACOMPLIA 20 mg filmsko obložene tablete rimonabant
Liver steatosis and a dose-related increase in centrilobular necrosis were observed in long-term studies in the rat. 
Med dolgotrajnimi študijami na podganah so opazili steatozo jeter in z odmerkom povezano povečanje centrilobularne nekroze.
Upper respiratory tract infection 
Infekcijske in parazitske bolezni okužba zgornjih dihal gastroenteritis
Always take ACOMPLIA exactly as your doctor has told you. 
Natančno upoštevajte zdravnikova navodila.
In adults, the recommended dosage is one 20 mg tablet daily to be taken in the morning before breakfast. 
Priporočeni odmerek za odrasle je ena 20 mg tableta na dan.
Tell your doctor before you start to take this medicine 
Bodite posebno pozorni pri jemanju zdravila ACOMPLIA Preden začnete jemati zdravilo, morate zdravniku povedati:
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blisters of the presentations of 30, 70 x 1 and 90 film-coated tablets 
Pretisni omoti s 30, 70 x 1 in 90 filmsko obloženo tableto
ACOMPLIA should be used with caution in patients with moderate hepatic impairment. 
Pri bolnikih z zmerno okvaro jeter je zdravilo ACOMPLIA potrebno uporabljati previdno.
Sleepiness (lethargy), tremor, night sweats, panic symptoms, hiccups, anger, restlessness (dysphoria), emotional disorder, suicidal thoughts, aggressiveness or aggressive behaviour, hypoglycaemia (low blood sugar). 
Občasni neželeni učinki, ki se pojavijo pri manj kot 1 od 100, a več kot 1 na 1000 oseb, in so bili zabeleženi pri bolnikih, ki so uporabljali zdravilo ACOMPLIA, vključujejo: zaspanost (letargija), drhtenje (tremor), nočno znojenje, simptome panike, kolcanje, jezo, nemir (disforijo), čustveno motnjo, samomorilne misli, agresivnost ali agresivno vedenje, hipoglikemija (nizek krvni sladkor).
There are no data in severe renal impairment. 
Podatkov za bolnike s hudo okvaro ledvic ni.
At two years, patients continuing on rimonabant had a mean total weight loss of 7.5 kg over 2 years whereas patients re-randomized to placebo group during the second year had a mean total weight loss of 3.1 kg over 2 years. 
V dveh letih je bilo pri bolnikih, ki so dobivali rimonabant, povprečno skupno zmanjšanje telesne mase 7,5 kg, pri bolnikih, ki so bili v drugem letu randomizirani v skupino s placebom, pa je bilo povprečno skupno zmanjšanje telesne mase v dveh letih 3,1 kg.V dveh letih je bila razlika v skupnem zmanjšanju telesne mase med zdravilom ACOMPLIA in placebom -4,2 kg (IZ95 % -5,0, -3,4; p<0,001).
At one year a mean weight loss of 5.3 kg was shown for ACOMPLIA 20 mg versus a loss on placebo of 1.4 kg (Difference -3.9 kg CI95% -4.6;-3.3 p<0.001). 
Ob uporabi 20 mg zdravila ACOMPLIA se je telesna masa po enem letu v povprečju zmanjšala za 5,3 kg, ob uporabi placeba pa za 1,4 kg (razlika -3,9 kg, IZ95 % -4,6; -3,3, p < 0,001).
Magyarország sanofi-aventis zrt., Magyarország Tel.: +36 1 505 0050 
Magyarország Tel.: +36 1 505 0050
• Seizures 
• Starostniki
Like all medicines, ACOMPLIA can cause side effects, although not everybody gets them Very common side effects, that affect more than 1 per 10, that have occurred in patients on ACOMPLIA include: nausea and upper respiratory tract infection. 
Zelo pogosti neželeni učinki, ki se pojavijo pri več kot 1 od 10 oseb in so bili zabeleženi pri bolnikih, ki so uporabljali zdravilo ACOMPLIA, vključujejo: slabost v želodcu in okužbo zgornjih dihal.
BEFORE YOU TAKE ACOMPLIA 
Če ste pozabili vzeti zdravilo ACOMPLIA
Significant mean weight reductions from baseline to one year for ACOMPLIA 20 mg versus placebo were demonstrated in three studies conducted in non-diabetic patients. 
V treh študijah pri nediabetičnih bolnikih so po enem letu zdravljenja z zdravilom ACOMPLIA 20 mg v primerjavi s placebom dokazali značilno zmanjšanje povprečne telesne mase od izhodišča.
Metabolism and nutrition disorders 
Presnovne in prehranske motnje hipoglikemija*
Contusion 
ZDRAVILA
A mean weight loss of 6.5 kg from baseline to one year was shown for ACOMPLIA 20 mg versus a mean weight loss of 1.6 kg for placebo (Difference -4.9 kg CI95% -5.3;-4.4, p< 0.001). 
Povprečno zmanjšanje telesne mase po enem letu v primerjavi z izhodiščem je bilo z zdravilom ACOMPLIA 20 mg 6,5 kg in s placebom 1,6 kg (razlika -4,9 kg, IZ95 % -5,3, -4,4; p<0,001).
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 20 mg of rimonabant. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena tableta vsebuje 20 mg rimonabanta.
− gastrointestinal disorders: abdominal pain. 
− bolezni prebavil: bolečina v trebuhu.
Table 1: System Organ Class 
Tabela 1: organski sistem zelo pogosti pogosti občasni redki
In a second trial in treatment naïve type 2 diabetic obese patients (Serenade), the absolute change in HbA1c (with a baseline of 7.9% for both groups) at six months was -0.8 for rimonabant 20 mg and -0.3 under placebo (Difference -0.51 CI95% -0.78, -0.24 p< 0.001). 
Absolutna sprememba HbA1c po šestih mesecih je bila v skupini, ki je prejemala 20 mg rimonabanta, -0,8 in v skupini, ki je prejemala placebo, -0,3 (razlika0,51, IZ95 % -0,78, -0,24, p < 0,001).
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blisters of the presentations of 14, 28, 56, 84 and 98 film-coated tablets 
Pretisni omoti s 14, 28, 56, 84 in 98 filmsko obloženimi tabletami
Rimonabant should not be used in patients with severe renal impairment (see section 4.2 and 5.2). 
Podatkov o bolnikih s hudo okvaro ledvic ni. Rimonabanta ne smete uporabljati pri bolnikih s hudo okvaro ledvic (glejte poglavji 4.2 in
Lethargy Tremor 
• Okvara jeter
− if you are breast-feeding 
− če dojite
Gastrointestinal disorders 
študije pri nediabetikih študija pri diabetikih placebo
CMDh agreement 
Dogovor skupine CMDh
The timetable for the implementation of the agreement is set out in Annex VI. 
Časovni razpored za izvajanje dogovora je opredeljen v Prilogi VI.
Numeta has been registered through the decentralised procedure (DCP) in Europe in 18 countries. 
Zdravilo Numeta je z decentraliziranim postopkom (DCP) registrirano v 18 evropskih državah.
1 Canadian Laboratory Initiative on PEdiatric Reference Intervals, http://www.caliperdatabase.com/caliperdatabase/controller?op=menu_reference_intervals&sm=0, accessed 29/08/2013 
1 Canadian Laboratory Initiative on PEdiatric Reference Intervals, http://www.caliperdatabase.com/caliperdatabase/controller?op=menu_reference_intervals&sm=0, dostop 29/08/2013.
• The PRAC also concluded that there was need for further risk minimisation measures such as information to healthcare professionals. 
• odbor PRAC je prav tako zaključil, da so potrebni dodatni ukrepi za zmanjšanje tveganja, na primer informacije za zdravstvene delavce.
b. the marketing authorisation holders should implement risk minimisation measures; 
b. imetniki dovoljenj za promet z zdravili izvajajo ukrepe za zmanjšanje tveganja;
Overall conclusion and conditions to the Marketing Authorisations 
Splošni zaključki in pogoji dovoljenj za promet z zdravili
In terms of efficacy measurements, the different Numeta formulations were able to maintain or increase body weight. 
V povezavi z merili za učinkovitost so različne formulacije zdravila Numeta vzdrževale ali povečale telesno maso.
The product information should be updated to inform health care professionals of the potential risk of hypermagnesemia and to provide monitoring advice particularly for more vulnerable subgroups. 
Informacije o zdravilu je treba posodobiti, tako da zdravstveno osebje obveščajo o morebitnem tveganju hipermagneziemije in vključujejo nasvet glede spremljanja, predvsem pri ranljivejših podskupinah.
“The MAH should liaise with the Reference Member State to agree on the appropriate procedure to be used for the fulfilment of this condition for lifting the suspension.” 
„Imetnik dovoljenja za promet z zdravilom se mora v sodelovanju z referenčno državo članico dogovoriti o ustreznem postopku, ki bo uporabljen za izpolnjevanje pogojev za preklic začasnega umika.“
• In addition, the magnesium level should be monitored at baseline and at appropriate intervals thereafter, in accordance with routine clinical practice and the needs of the individual patient. 
• Poleg tega je treba na izhodišču in pozneje v ustreznih presledkih spremljati ravni magnezija, skladno z rutinsko klinično prakso in potrebami posameznega bolnika.
Consequently there is a potential risk for hypermagnesemia particularly in patients with reduced renal function. 
Posledično je prisotno tveganje hipermagneziemije, predvsem pri bolnikih z zmanjšanim ledvičnim delovanjem.
Pursuant to Article 6(1)(d) of Regulation (EC) No 1901/2006 as amended, the PDCO's opinion on Numeta was sought in the context of this review. 
Skladno s členom 6(1)(d) Uredbe (ES) št. 1901/2006, kot je bila spremenjena, je pediatrični odbor PDCO svoje mnenje podal na podlagi tega pregleda.
For the suspension to be lifted, the National competent authorities of Member States shall verify that the following conditions are fulfilled by the MAH: 
Za preklic začasnega umika morajo nacionalni pristojni organi držav članic preveriti, ali imetnik dovoljenja za promet z zdravilom izpolnjuje naslednje pogoje:
It should be noted that clinical signs may not be identifiable unless hypermagnesaemia is severe. 
Treba je izpostaviti, da klinični znaki morda ne bodo opazni, dokler hipermagneziemija ne postane resna.
A DHPC was agreed, together with the timelines for distribution; 
Potrjena je bila neposredna komunikacija z zdravstvenimi delavci, skupaj z urnikom distribucije;
Most patients with hypomagnesemia show no acute symptoms but it can still lead to osteoporosis and is correlated to increased inflammation and metabolic syndrome. 
Večina bolnikov s hipomagneziemijo nima akutnih simptomov, vendar lahko kljub temu povzroči osteoporozo in je povezana s povečanim vnetjem ter presnovnim sindromom.
PN solutions are delivered through a peripheral or central venous catheter. 
Raztopine za parenteralno prehrano se dovajajo prek perifernega ali centralnega venskega katetra.
Magnesium is an important electrolyte, particularly for a preterm infant. 
Magnezij je pomemben elektrolit, predvsem pri nedonošenčkih.
The risk of hypermagnesemia and all measures considered necessary to mitigate this risk (i.e. agreed additional pharmacovigilance activities, as listed above and risk minimisation activities such as direct healthcare professional communication (DHPC), changes to the product information) should be reflected in a revised risk management plan (RMP), which should also include proposals for evaluating the effectiveness of the risk minimisation activities. 
Tveganje hipermagneziemije in vse ukrepe, potrebne za zmanjševanje tega tveganja (tj. dogovorjene dodatne farmakovigilančne dejavnosti, navedene zgoraj, ter dejavnosti za zmanjševanje tveganja, kot je neposredna komunikacija z zdravstvenimi delavci, spremembe informacij o zdravilu), je treba vključiti v posodobljen načrt obvladovanja tveganja (RMP), ki naj prav tako vsebuje predloge za vrednotenje učinkovitosti dejavnosti za zmanjševanje tveganja.
In addition, recent data highlighted by the PDCO suggest paediatric reference ranges for magnesium may be higher than previously thought (Canadian Laboratory Initiative on PEdiatric Reference Intervals [CALIPER]1). 
Poleg tega novi podatki, ki jih je izpostavil odbor PDCO, kažejo, da so lahko pediatrični referenčni razponi za magnezij večji, kot so menili prej (Pobuda kanadskih laboratorijev za referenčne intervale v pediatriji [CALIPER]1).
Overall Numeta was found to be acceptable to paediatric clinical staff in terms of handling, ease of use and time from prescription to infusion. 
Na splošno so ugotovili, da je bilo zdravilo Numeta sprejemljivo za pediatrično klinično osebje glede ravnanja, preprostosti uporabe in časa od predpisovanja do infundiranja.
These risks are considered to be complications of PN use in general as outlined in the joint paper on paediatric PN the European society of paediatric gastroenterology, hepatology and nutrition (ESPGHAN) and the European society for clinical nutrition and metabolism (ESPEN). 
Menijo, da so ta tveganja splošni zapleti parenteralne uporabe, kot je opisano v skupnem članku o pediatrični parenteralni prehrani, ki sta ga pripravila Evropsko združenje za pediatrično gastroenterologijo, hepatologijo in prehrano (European society of paediatric gastroenterology, hepatology and nutrition - ESPGHAN) ter Evropsko združenje za klinično prehrano in presnovo (European society for clinical nutrition and metabolism - ESPEN).
The primary objective of this study was to provide daily information on the performance safety of the range of Numeta products in practical therapeutic use for the 5 days of the study and during an optional treatment period in preterm newborn infants. 
Primarni cilj te študije je bil pridobiti dnevne podatke o varnosti delovanja nabora zdravil Numeta pri praktični terapevtski uporabi v 5 dneh študije in med obdobjem neobveznega zdravljenja nedonošenčkov.
The levels of magnesium reported in these case reports ranged mainly from 1.025mmol/L to > 1.5mmol/L with levels greater than 1.2mmol/L reported in 9 out of 14 cases while one case was reported as > 1.5mmol/L. 
Ravni magnezija v teh poročilih primerov so se gibale od 1,025 mmol/l do > 1,5 mmol/l, pri čemer so pri 9 od 14 primerov poročali o ravneh, višjih od 1,2 mmol/l, pri enem primeru pa o ravni > 1,5 mmol/l.
In order to prevent any potential harm to premature infants, the MAH decided to recall the product from the market. 
Da bi preprečil kakršno koli morebitno škodo pri nedonošenčkih, se je imetnik dovoljenja za promet z zdravilom odločil, da zdravilo odpokliče s trga.
c. the marketing authorisations of Numeta G16%E should be varied (in accordance with changes to the product information as set out in Annex IV). 
c. je treba dovoljenja za promet z zdravilom Numeta G16%E spremeniti (skladno s spremembami informacij o zdravilu, določenih v Prilogi IV).
The PRAC also recommended that the MAH should submit a revised RMP within 3 months after finalisation of the procedure including proposals for evaluating the effectiveness of the risk minimisation activities. 
Odbor PRAC je prav tako priporočil, naj imetnik dovoljenja za promet z zdravilom predloži posodobljen načrt obvladovanja tveganja (RMP) v 3 mesecih po koncu postopka, vključno s predlogi za vrednotenje učinkovitosti dejavnosti za zmanjševanje tveganja.
Magnesium has been shown to improve neurological outcome for premature babies when given antenatally to the mother (Doyle et al, 2010) and is thought to have neuroprotective effects also in other circumstances. 
Pokazali so, da magnezij izboljša nevrološki izid pri nedonošenčkih, če se daje materi pred porodom (Doyle in sod., 2010), in da ima nevroprotektivne učinke tudi v drugih okoliščinah.
Parenteral nutrition (PN) is the use of intravenous macronutrients, electrolytes, micronutrients and fluids to provide nutritional support in patients who cannot be fed by oral or enteral nutrition. 
Parenteralna prehrana je uporaba intravenskih makrohranil, elektrolitov, mikrohranil in tekočin, ki omogočajo prehransko podporo pri bolnikih, ki se niso zmožni prehranjevati peroralno ali enteralno.
The PRAC considered that a DHPC was needed to communicate the outcome of the present review to relevant healthcare professionals. 
Odbor PRAC je menil, da je za sporočanje izida trenutnega pregleda zadevnemu zdravstvenemu osebju potrebna neposredna komunikacija z zdravstvenimi delavci (DHPC).
Hypermagnesaemia is a serious clinical condition which can lead to generalised weakness, respiratory failure, hypotension, arrhythmias (especially if not otherwise explained by the clinical condition of the infant/child). 
Hipermagneziemija je resno klinično stanje, ki lahko povzroči generalizirano šibkost, dihalno odpoved, hipotenzijo, aritmije (predvsem, če tega ni mogoče drugače razložiti na podlagi kliničnega stanja dojenčka/otroka).
The initial application for Numeta G13%E and Numeta G16%E was supported by a prospective, multicentre, non-comparative, open-label phase 3 study (Ped3CB/P01/06/MuB). 
Prvotno vlogo za zdravili Numeta G13%E in Numeta G16%E je podprla prospektivna, multicentrična, neprimerjalna, odprta študija 3. faze (Ped3CB/P01/06/MuB).
The magnesium content of Numeta G13%E is 0.43mmol/100mL. 
Vsebnost magnezija v zdravilu Numeta G13%E je 0,43 mmol/100 ml.
The safety concerns of Numeta products outlined in the initial application and risk management plan include drug administration errors, use of Numeta in patients with hypersensitivity to one of the components, use of Numeta in patients with severe metabolic disease, catheter-related infection and sepsis, re-feeding syndrome, use of Numeta in patients with certain organ impairment and extravasation and thrombophlebitis when peripherally administered. 
Varnostne težave pri zdravilih Numeta, navedene v prvotni vlogi in načrtu obvladovanja tveganja, vključujejo napake pri dajanju zdravila, uporabo zdravila Numeta pri bolnikih s preobčutljivostjo na eno od sestavin, uporabo zdravila Numeta pri bolnikih s hudo presnovno boleznijo, s katetrom povezano okužbo ter sepso, sindrom ponovnega hranjenja, uporabo zdravila Numeta pri bolnikih z določeno organsko okvaro in ekstravazacijo ter tromboflebitisom, kadar se daje periferno.
Therefore, in summary, there is no unconfounded report of hypermagnesemia with Numeta G16%E, no evidence of harm and there are uncertainties in relation to paediatric reference ranges for magnesium which may be higher than previously thought. 
Če povzamemo, ni nobenega zanesljivega poročila o hipermagneziemiji pri zdravilu Numeta G16%E, nobenih dokazov o škodi, obstajajo pa negotovosti, povezane s pediatričnimi referenčnimi razponi za magnezij, ki so lahko večji, kot so menili prej.
Numeta G13%E and Numeta G16%E are industrially manufactured, heat sterilised parenteral nutrition solutions (glucose, lipids, amino acids and electrolytes). 
Zdravili Numeta G13%E in Numeta G16%E sta industrijsko izdelani, toplotno sterilizirani raztopini za parenteralno prehrano (glukoza, lipidi, aminokisline in elektroliti).
Early recognition and treatment of hypermagnesemia may prevent or minimise life-threatening events, however the vast majority of mild hypermagnesaemia patients may be missed as measurement of magnesium levels is not routine in clinical practice. 
Zgodnje odkrivanje in zdravljenje hipermagneziemije lahko preprečita ali zmanjšata smrtno nevarne dogodke, vendar se to lahko spregleda pri večini bolnikov z blago hipermagneziemijo, saj meritve ravni magnezija v klinični praksi niso rutinske.
The ESPEN/ESPGHAN guideline recommends a lower magnesium intake of 0.2mmol/kg/d for infants of 0-12 months of age and 0.1mmol/kg/d for children between 1 to 13 years of age. 
Smernica ESPEN/ESPGHAN priporoča manjši vnos magnezija, ki je 0,2 mmol/kg/dan za dojenčke, stare 0-12 mesecev, in 0,1 mmol/kg/dan za otroke, stare od 1 do 13 let.
If serum magnesium levels are elevated the infusion of Numeta G16%E should be stopped or infusion rate reduced as deemed clinically appropriate and safe. 
Če so ravni magnezija v serumu povišane, je treba infundiranje zdravila Numeta G16%E prekiniti ali zmanjšati hitrost infundiranja, kot je klinično primerno in varno;
Numeta G16%E Having considered the overall submitted data provided by the MAH in writing, the stakeholder's submission and the PDCO advice, the PRAC concluded that: a. the marketing authorisation holders should sponsor a post-authorisation safety study together with the follow up evaluation of the results of that study; b. the marketing authorisation holders should implement risk minimisation measures; c. the marketing authorisations should be varied. 
Numeta G16%E Po preučitvi vseh podatkov, ki jih je v pisni obliki predložil imetnik dovoljenja za promet z zdravilom, prošnje zainteresirane strani in nasveta odbora PDCO je odbor PRAC zaključil, da: a. morajo imetniki dovoljenj za promet z zdravili sponzorirati študijo o varnosti zdravila v obdobju trženja in nadaljnje vrednotenje rezultatov študije; b. naj imetniki dovoljenj za promet z zdravili izvajajo ukrepe za zmanjšanje tveganja; c. so potrebne spremembe dovoljenj za promet z zdravili.
This is especially important in those patients at increased risk of developing hypermagnesaemia including patients with impaired renal function, patients receiving other medicinal products which place them at risk of developing hypermagnesaemia or patients receiving magnesium from other sources, including neonates whose mother's recently received magnesium in the antepartum period. 
To je še posebej pomembno pri bolnikih s povečanim tveganjem za razvoj hipermagneziemije, vključno z bolniki s poslabšanim ledvičnim delovanjem, bolniki, ki prejemajo druga zdravila, ki jih izpostavijo tveganju za razvoj hipermagneziemije, ali bolniki, ki prejemajo magnezij iz drugih virov, kot so novorojenčki, katerih matere so pred porodom prejemale magnezij.
Magnesium serves several important functions in the human body; it is a co-factor for DNA and protein synthesis, oxidative phosphorylation, enzyme activity and regulation of parathyroid hormone secretion (Volpe, 2013; Ayuk & Gittoes, 2011; Shils et al, 1999). 
Ima več pomembnih funkcij v telesu: je kofaktor (sodelujoči dejavnik) pri sintezi DNK ter beljakovin, oksidativni fosforilaciji, dejavnosti encimov in uravnavanju izločanja paratiroidnih hormonov (Volpe, 2013; Ayuk & Gittoes, 2011; Shils in sod., 1999).
This magnesium intake with Numeta G13%E appears higher than the recommendation of the American Society of Parenteral and Enteral Nutrition (ASPEN) and ESPGHAN/ESPEN guidelines for preterm neonates (0.15 to 0.25mmol/kg/d and 0.13-0.25mmol/kg/d respectively). 
Ta vnos magnezija z zdravilom Numeta G13%E je videti večji od priporočil Ameriškega združenja za parenteralno in enteralno prehrano (American Society of Parenteral and Enteral Nutrition - ASPEN) in smernic ESPGHAN/ESPEN za nedonošenčke (od 0,15 do 0,25 mmol/kg/dan oziroma od 0,13 do 0,25 mmol/kg/dan).
Magnesium also plays a critical role in maintaining normal nerve and muscle function, cardiac excitability, neuromuscular conduction, muscular contraction, vasomotor tone and for a balanced immune response (Brandao et al, 2013). 
Magnezij ima prav tako ključno vlogo pri vzdrževanju normalnega delovanja živcev in mišic, srčni vzdržljivosti, živčno-mišični prevodnosti, krčenju mišic, vazomotoričnem tonusu ter uravnovešenem imunskem odzivu (Brandao in sod., 2013).